Tag Archives: Myers

Bristol Myers, hot off Breyanzi nod, plots new cell therapy factory in Massachusetts

Bristol Myers Squibb, freshly armed with an approval for its CAR-T lymphoma therapy Breyanzi, is making a major cell therapy manufacturing play. The company is building out a new 244,000-square-foot cell therapy site, housed at the company’s 89-acre campus in Devens, Massachusetts. The new factory will be kitted out to quickly ramp up clinical and commercial production, augmenting Bristol’s existing… Read More »

Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients

As one of the hottest markets in pharmaceuticals, immunology has become a murderers’ row of blockbuster drugs in recent years. But Bristol Myers Squibb has big hopes for a next-gen entry in Zeposia, and it’s angling for a foothold in ulcerative colitis to get the ball rolling.  Zeposia helped 18.4% of ulcerative colitis patients reach clinical remission at… Read More »

Bristol Myers Squibb’s Opdivo-Yervoy combo helps mesothelioma patients live longer

Bristol-Myers Squibb’s Opdivo-Yervoy combo is awaiting some critical decisions in non-small cell lung cancer, but in the meantime, it’s making its mark in a smaller indication, too. The immuno-oncology duo topped chemo at extending the lives of phase 3 trial patients with previously untreated malignant pleural mesothelioma (MPM), the company said Monday. The rare cancer,… Read More »

Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo

Bristol Myers Squibb’s Opdivo-Yervoy immuno-oncology combo has had some ups and downs lately. But it can now claim a new FDA nod in pretreated liver cancer. The Opdivo-Yervoy regimen is now FDA-approved to treat hepatocellular carcinoma patients who have previously received Bayer’s standard-of-care Nexavar, Bristol said Wednesday. Because the FDA doled out the indication under… Read More »